AsiDNA (etidaligide) / Valerio Therap 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   10 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AsiDNA (etidaligide) / Valerio Therap
2020-000825-18: Safety and efficacy study to evaluate AsiDNA in addition with Niraparib for treatment of relapsed platinum sensitive ovarian cancer already treated with Niraparib since at least 6 months

Ongoing
1/2
26
Europe
AsiDNA, Powder for solution for infusion
Gustave Roussy, Onxeo S.A.
Relapsed platinum sensitive ovarian cancer, Relapsed platinum sensitive ovarian cancer, Diseases [C] - Cancer [C04]
 
 
AsiDNA, NCT05394558: Children, Adolescents and Young Adults

Terminated
1/2
8
Europe
AsiDNA
Institut Curie
Recurrent High-grade Glioma
09/23
09/23
REVOCAN, NCT04826198 / 2020-000825-18: Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Terminated
1/2
13
Europe
AsiDNA, Niraparib, Olaparib, Rucaparib
Gustave Roussy, Cancer Campus, Grand Paris, Onxeo S.A.
Ovarian Cancer
04/24
04/24
NCT05700669: Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

Completed
1/2
3
US
AsiDNA, Olaparib
Valerio Therapeutics
Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer
10/23
10/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AsiDNA (etidaligide) / Valerio Therap
2020-000825-18: Safety and efficacy study to evaluate AsiDNA in addition with Niraparib for treatment of relapsed platinum sensitive ovarian cancer already treated with Niraparib since at least 6 months

Ongoing
1/2
26
Europe
AsiDNA, Powder for solution for infusion
Gustave Roussy, Onxeo S.A.
Relapsed platinum sensitive ovarian cancer, Relapsed platinum sensitive ovarian cancer, Diseases [C] - Cancer [C04]
 
 
AsiDNA, NCT05394558: Children, Adolescents and Young Adults

Terminated
1/2
8
Europe
AsiDNA
Institut Curie
Recurrent High-grade Glioma
09/23
09/23
REVOCAN, NCT04826198 / 2020-000825-18: Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Terminated
1/2
13
Europe
AsiDNA, Niraparib, Olaparib, Rucaparib
Gustave Roussy, Cancer Campus, Grand Paris, Onxeo S.A.
Ovarian Cancer
04/24
04/24
NCT05700669: Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

Completed
1/2
3
US
AsiDNA, Olaparib
Valerio Therapeutics
Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer
10/23
10/23

Download Options